Timing of new black box warnings and withdrawals for prescription medications
about
sameAs
Comparison of evidence on harms of medical interventions in randomized and nonrandomized studiesRole of reactive metabolites in the circulation in extrahepatic toxicityNovel in vitro and mathematical models for the prediction of chemical toxicityThe role of concentration-effect relationships in the assessment of QTc interval prolongationBisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectEvaluation of database-derived pathway development for enabling biomarker discovery for hepatotoxicityHow to promote adverse drug reaction reports using information systems - a systematic review and meta-analysisThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityWhat are the public health effects of direct-to-consumer drug advertising?Market withdrawal of new molecular entities approved in the United States from 1980 to 2009On the relative safety of parenteral iron formulationsCardiomyocyte MEA data analysis (CardioMDA)--a novel field potential data analysis software for pluripotent stem cell derived cardiomyocytesGenome Sequence Variability Predicts Drug Precautions and Withdrawals from the MarketDisseminating drug prescribing information: the cox-2 inhibitors withdrawals.Drug- and non-drug-associated QT interval prolongation.A review of pharmaceutical labeling for overdose treatment and toxicity data.Direct hydrogel encapsulation of pluripotent stem cells enables ontomimetic differentiation and growth of engineered human heart tissues.Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre.Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data.Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.Predicting in vivo drug interactions from in vitro drug discovery data.Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public dataThrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature.The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.Ethical considerations in the collection of genetic data from critically ill patients: what do published studies reveal about potential directions for empirical ethics research?The association of serum testosterone levels and ventricular repolarizationRisk, responsibility, and generic drugs.Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes.Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.Discontinuation of thioridazine. Risks must be balancedHow safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009Assessing general side effects in clinical trials: reference data from the general population.Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.Drug withdrawals from the Canadian market for safety reasons, 1963-2004.Deliberate self-harm (and attempted suicide).The PharmWatch programme: challenges to engaging the community pharmacists in Jamaica.Mining FDA drug labels using an unsupervised learning technique--topic modeling
P2860
Q24282604-9A44C3A8-E0EC-4F3A-B776-FD867D230241Q26849288-EADE17DF-B3AD-4FB7-ADC0-6F4830456922Q26851492-897603B7-51BB-4935-A122-FAC9FACF8D4BQ26866417-40158B7D-DCE9-405F-AC4A-0BF74EA13ADAQ27026618-FB28BC48-7F97-41BE-BFE1-5A11E146F71CQ27027301-BCAA0E7D-C0CF-44DE-938C-D5061096DD1FQ28070314-3BF7B35C-9AB9-49A1-BB02-44EDAB6E7A0AQ28080256-04B1B618-3768-4CCF-9CEF-1FEC7508CC1DQ28195995-AFFA5196-D7A0-4C94-AA82-0BBAB1F9FEA9Q28237701-96D22945-D5E7-4A58-AB56-F45A762B8552Q28262418-70A36141-2C27-4416-99FB-B7C572D70FE6Q28533644-8B72EEEC-1B2D-4156-850D-6133CC6BBC19Q28554426-BD9E6D92-7133-4B38-96D9-D6AD6352E781Q30440234-8DF20558-D287-4018-A20A-2EBE3A4FD933Q30474909-EFEF315A-9FA0-42BC-B485-A923664BCCFBQ30584220-D9832840-A128-4EDC-A809-BF6379635FB5Q30731784-DFA5475E-69F4-4F09-9715-85A0697C7332Q30832167-FEF97B26-4FFA-49D5-994F-53DC3E16B528Q30887490-991ABFD8-1EFC-4C9E-A4C4-41051A5DBF6EQ30936137-A45A189F-A043-48AF-B6D8-884A20200EB7Q30985349-C7B59DD8-AE84-4A12-B687-1DDDBB8E7F4DQ31011412-F0615384-A453-4C65-A9DA-DFCE120A0BA5Q31043369-E7682639-85C3-4F9B-9A26-B2C0F649AD8DQ33398293-19D1F03A-950D-4FE4-B33C-4910767A4651Q33411837-4110DECD-3400-4B55-8F33-C85011C12DBFQ33517601-B5F0375B-AB45-4D61-926C-F7FF5B657D83Q33596419-3A4D9F9B-617C-4CC3-A607-2AA1027F03B9Q33675147-2F0FD843-D967-4702-82F6-969050797BE5Q33725796-BA1707DA-A13A-4CE0-A9A4-9558A956FC57Q33750834-3C2B0442-DD12-48E1-A980-903B3663EB43Q33790423-B9EC4296-5E5E-47AB-A593-662E94B15B11Q33812605-C9B1E3F1-2226-4E60-A060-AF64F08D05EAQ33856799-343A1725-A882-40CE-836F-9575FBDBF0FFQ33856964-33F10BF9-9221-44E2-B12E-0F3C92BDC9E9Q33890476-35790F8B-DAA4-4814-93CE-72891CB1A3CAQ33891043-20E08159-B60A-439D-937A-EB505E65AF68Q33927245-4C0ED8A4-914C-49EF-910E-A87FC8BB5334Q34011331-234B444B-0070-4BCA-8434-817A86EE3DA8Q34078477-62718FF5-02FF-4EFA-929B-0CA2ECE41603Q34099817-57EE4600-987E-4802-AD58-820D077D7AA7
P2860
Timing of new black box warnings and withdrawals for prescription medications
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Timing of new black box warnings and withdrawals for prescription medications
@ast
Timing of new black box warnings and withdrawals for prescription medications
@en
Timing of new black box warnings and withdrawals for prescription medications
@nl
type
label
Timing of new black box warnings and withdrawals for prescription medications
@ast
Timing of new black box warnings and withdrawals for prescription medications
@en
Timing of new black box warnings and withdrawals for prescription medications
@nl
prefLabel
Timing of new black box warnings and withdrawals for prescription medications
@ast
Timing of new black box warnings and withdrawals for prescription medications
@en
Timing of new black box warnings and withdrawals for prescription medications
@nl
P2093
P3181
P356
P1476
Timing of new black box warnings and withdrawals for prescription medications
@en
P2093
David H Bor
Paul D Allen
Sidney M Wolfe
Steffie J Woolhandler
P304
P3181
P356
10.1001/JAMA.287.17.2215
P407
P577
2002-05-01T00:00:00Z